World Heart to complete initial testing soon
This article was originally published in Clinica
Executive Summary
World Heart, a Canadian developer of an artificial heart, expects to complete in vitro and animal testing of its first product, the HeartSaver VAD, by the middle of the year. The company based in Ottawa, Ontario, raised $19 million in its initial public offering last year. The HeartSaver is the first pulsatile ventricular assist device (VAD) designed to be permanently implanted in the chest cavity alongside the natural heart. Pilot production of prototypes and long-term animal testing is expected to begin before the end of the year. Clinical trials are scheduled for 1999.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.